Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2024-02-12 Orexo Orexo och Sobi avancerar förstudie med AmorphOX Pressreleaser Ladda ner | Visa Stäng
2024-02-12 Orexo Orexo and Sobi agree to advance feasibility study with AmorphOX Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 12 Feb 2024 | Orexo

Orexo and Sobi agree to advance feasibility study with AmorphOX

  • The feasibility study confirmed that the biomolecule retained its activity after formulation with AmorphOX
  • Orexo has patent applications for AmorphOX formulations relating to biomolecules.

Uppsala, Sweden – February 12, 2024 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company agreed with Swedish Orphan Biovitrum AB (publ.) (Sobi) to advance the successful exploratory feasibility study initiated last year. The feasibility study primarily assessed whether the biomolecule could be formulated in AmorphOX with retained activity. The continued collaboration will evaluate if the AmorphOX technology could add unique properties to one of Sobi’s biomolecules.

Orexo has tested enzymes, peptides and proteins in AmorphOX and seen retained activity and significant improvement in stability compared to other formulations in a wide range of storage temperatures. A core strategy to expand the use of AmorphOX is to test AmorphOX in combination with molecules controlled by other companies. Sobi is the second company agreeing to advance the project beyond the initial exploratory feasibility study.   

Nikolaj Sørensen, President and CEO of Orexo, said, ”Sobi is a leading biopharmaceutical company, and we are pleased to see how the unique properties of AmorphOX can be successfully applied to one of Sobi’s biomolecules. Advancing the collaboration is another proof of concept for AmorphOX and with the combined expertise of the companies I am certain we can learn more about the value potential for our scalable drug delivery platform. The collaboration is still in an early development stage, but with the ambition to continue show successful results, the collaboration has the potential to proceed into a development program of a new and differentiated pharmaceutical product.”

Orexo AB (publ.)

Nikolaj Sørensen, Lena Wange, IR & Communications Director
President and CEO
Tel: +46 (0)18780 Tel: +46 (0)18780 88 00
88 00
E-mail: E-mail: ir@orexo.com
ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm’s main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on X (former Twitter), LinkedIn, and YouTube.

About AmorphOX®

Orexo’s proprietary drug delivery platform, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients.

The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid and extensive drug exposure. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies.

About Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.

More about Sobi at sobi.com, LinkedIn and YouTube.

The information was submitted for publication at 8.00 CET on February 12, 2024

2024-02-08 Orexo Orexo delårsrapport kv 4 2023, inkl. bokslutskommuniké Rapporter Ladda ner | Visa Stäng
2024-02-08 Orexo Orexo Interim Report Q4 2023, incl. Full Year Report Rapporter Ladda ner | Visa Stäng
2024-02-06 Orexo Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC Pressreleaser Ladda ner | Visa Stäng
2024-02-06 Orexo Orexos studieresultat för OX640 presenteras vid AAAAI:s Annual Meeting 2024 i Washington, DC, USA Pressreleaser Ladda ner | Visa Stäng
2024-02-01 Penser Access by Carnegie Penser Access by Carnegie: Orexo - Motvind från valutan Pressreleaser Visa Stäng
2023-11-29 Penser Access Penser Access: Interview with Orexo - Erik Penser Bank - Nov 29th 2023 Pressreleaser Visa Stäng
2023-11-28 Orexo Orexo meddelar att FDA accepterat registreringsansökan för granskning av OX124, ett högdosläkemedel vid opioidöverdos Pressreleaser Ladda ner | Visa Stäng
2023-11-28 Orexo Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose Pressreleaser Ladda ner | Visa Stäng
2023-11-06 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 6 november 2023 Pressreleaser Visa Stäng
2023-11-03 Penser Access Penser Access: Går mot lönsamhet, men tillväxten dröjer - Orexo Pressreleaser Visa Stäng
2023-11-02 Orexo Orexo Q3 2023 Interim Report Rapporter Ladda ner | Visa Stäng
2023-11-02 Orexo Orexo delårsrapport kv 3 2023 Rapporter Ladda ner | Visa Stäng
2023-10-27 Orexo Orexo announces changes in the company's Board of Directors Pressreleaser Ladda ner | Visa Stäng
2023-10-27 Orexo Orexo meddelar förändringar i styrelsen Pressreleaser Ladda ner | Visa Stäng
2023-10-26 Orexo Orexo:s valberedning inför årsstämman 2024 Pressreleaser Ladda ner | Visa Stäng
2023-10-26 Orexo Orexo's Nomination Committee for the Annual General Meeting 2024 Pressreleaser Ladda ner | Visa Stäng
2023-10-26 Orexo Kommuniké från Orexo:s extra bolagsstämma Pressreleaser Ladda ner | Visa Stäng
2023-10-26 Orexo Report from Orexo's extraordinary general meeting Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Orexo Orexo offentliggör data från MODIA-studien som utvärderar effekten på användning av otillåtna opioider Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Orexo Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids Pressreleaser Ladda ner | Visa Stäng
2023-10-02 Orexo Kallelse till extra bolagsstämma i Orexo AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-10-02 Orexo Notice of Extraordinary General Meeting in Orexo AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-10-02 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 2 oktober 2023 Pressreleaser Visa Stäng
2023-09-27 Orexo BioStock Investor Meeting: Orexo Pressreleaser Visa Stäng
2023-09-27 Orexo BioStock Investor Meeting: Orexo Pressreleaser Visa Stäng
2023-09-18 Orexo Orexo lämnar in registreringsansökan till FDA för OX124, ett högdos-läkemedel vid opioidöverdos Pressreleaser Ladda ner | Visa Stäng
2023-09-18 Orexo Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose Pressreleaser Ladda ner | Visa Stäng
2023-09-05 Orexo Orexo deltar i Pareto Securities 14[th] Annual Healthcare Conference 2023 Pressreleaser Ladda ner | Visa Stäng
2023-09-05 Orexo Orexo to participate in Pareto Securities' 14[th] Annual Healthcare Conference 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-29 Orexo Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product Pressreleaser Ladda ner | Visa Stäng
2023-08-29 Orexo Orexo säkrar patentskydd i USA för OX640, ett pulverbaserat nasalt adrenalinläkemedel Pressreleaser Ladda ner | Visa Stäng
2023-07-24 Orexo Orexo's patent win for ZUBSOLV[®] appealed Pressreleaser Ladda ner | Visa Stäng
2023-07-24 Orexo Orexo:s seger i patenttvisten för ZUBSOLV[®] överklagas Pressreleaser Ladda ner | Visa Stäng
2023-07-20 Penser Access Penser Access: Det har vänt, men värderingen släpar - Orexo Pressreleaser Visa Stäng
2023-07-19 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 19 juli 2023 Pressreleaser Visa Stäng
2023-07-18 Orexo Orexo delårsrapport kv 2 2023 Rapporter Ladda ner | Visa Stäng
2023-07-18 Orexo Orexo Q2 2023 Interim Report Rapporter Ladda ner | Visa Stäng
2023-07-03 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 3 juli 2023 Pressreleaser Visa Stäng
2023-07-03 Penser Access Penser Access: Segrar i patenttvist - Orexo Pressreleaser Visa Stäng
2023-07-01 Orexo Orexo vinner patenttvist för ZUBSOLV® i USA Pressreleaser Ladda ner | Visa Stäng
2023-07-01 Orexo Orexo wins patent litigation for ZUBSOLV® in the US Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Penser Access Penser Access: Krisvärdering inför viktiga besked - Orexo Pressreleaser Visa Stäng
2023-05-03 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 2 maj 2023 Pressreleaser Visa Stäng
2023-04-27 Orexo Orexo Interim Report Q1 2023 Rapporter Ladda ner | Visa Stäng
2023-04-27 Orexo Orexo delårsrapport kv 1 2023 Rapporter Ladda ner | Visa Stäng
2023-04-18 Orexo Kommuniké från Orexo AB:s årsstämma Pressreleaser Ladda ner | Visa Stäng
2023-04-18 Orexo Report from Orexo AB's annual general meeting Pressreleaser Ladda ner | Visa Stäng
2023-04-04 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 3 april 2023 Pressreleaser Visa Stäng
2023-04-03 Orexo Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124 Pressreleaser Ladda ner | Visa Stäng
2023-04-03 Orexo Orexo uppdaterar tidplanen för högdosläkemedlet vid opioidöverdos, OX124 Pressreleaser Ladda ner | Visa Stäng
2023-03-28 Orexo Orexo publishes the Annual and Sustainability Report for 2022 Rapporter Ladda ner | Visa Stäng
2023-03-28 Orexo Orexo publicerar års- och hållbarhetsredovisning för 2022 Rapporter Ladda ner | Visa Stäng
2023-03-15 Orexo Orexo postpones publication of the Annual Report Pressreleaser Visa Stäng
2023-03-15 Orexo Orexo senarelägger publicering av årsredovisning Pressreleaser Visa Stäng
2023-03-15 Orexo Kallelse till årsstämma i Orexo Pressreleaser Ladda ner | Visa Stäng
2023-03-15 Orexo Notice of Annual General Meeting of Orexo Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

26 Apr 2024 | Årsstämma 2023
29 Apr 2024 | Årligutdelning
8 May 2024 | Kvartalsrapport 2024-Q1
17 Jul 2024 | Kvartalsrapport 2024-Q2
14 Nov 2024 | Kvartalsrapport 2024-Q3
6 Feb 2025 | Bokslutskommuniké 2024